◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CYTK

Cytokinetics Inc (CYTK) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Cytokinetics Inc (CYTK) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 673 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, CYTK reported $88M in revenue and ($785M) in net income.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.

Interactive charts & full statements → Open the CYTK valuation workbench →

CYTK Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$68M	$88M	$18M	$8M	$95M	$70M	$56M	$27M	$32M	$13M	$106M	$29M	$47M	$31M	$8M	$4M	$3M	$82M	$12M	$14M	$3M
Gross Profit	$54M	$78M	($321M)	($323M)	($146M)	($90M)	($41M)	($59M)	($58M)	($77M)	$47M	($18M)	$3M	($19M)	($28M)	$4M	$3M	$82M	$12M	$14M	$3M
Gross Margin %	79.4%	88.5%	-1737.2%	-4284.1%	-154.6%	-127.1%	-73.7%	-220.5%	-183.0%	-575.5%	43.7%	-61.9%	5.4%	-61.4%	-371.5%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($708M)	($612M)	($536M)	($496M)	($324M)	($186M)	($94M)	($99M)	($89M)	($113M)	$19M	($37M)	($15M)	($34M)	($39M)	($48M)	($50M)	$26M	($59M)	($56M)	($61M)
Operating Margin %	-1041.2%	-695.4%	-2902.7%	-6589.7%	-342.8%	-264.5%	-168.3%	-368.0%	-282.3%	-848.3%	17.6%	-130.5%	-31.4%	-110.6%	-517.3%	-1199.1%	-1926.1%	32.0%	-475.7%	-414.7%	-1961.6%
Net Income	($894M)	($785M)	($590M)	($526M)	($389M)	($215M)	($127M)	($122M)	($106M)	($128M)	$16M	($38M)	($15M)	($34M)	($42M)	($48M)	($49M)	$25M	($56M)	($49M)	($57M)
Net Margin %	-1314.7%	-891.6%	-3191.1%	-6988.6%	-411.2%	-305.7%	-228.0%	-452.9%	-337.4%	-955.9%	15.5%	-130.9%	-31.2%	-110.0%	-551.4%	-1196.5%	-1912.6%	30.1%	-453.9%	-358.9%	-1826.5%
EBITDA	—	($775M)	($493M)	($457M)	($329M)	($176M)	($87M)	($93M)	($83M)	($109M)	$19M	($37M)	($14M)	($33M)	($40M)	($47M)	($48M)	$27M	($53M)	($45M)	($54M)
Earnings Per Share (EPS)	$-7.21	$-6.54	$-5.26	$-5.45	$-4.33	$-2.80	$-1.97	$-2.11	$-1.95	$-2.59	$0.39	$-0.97	$-0.41	$-1.24	$-2.30	$-4.06	$-4.61	$2.54	$-6.85	$-6.16	$-9.36
Shares Outstanding (M)	—	120M	112M	97M	90M	77M	65M	58M	54M	49M	43M	39M	36M	27M	18M	12M	11M	10M	8M	8M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$29M	$19M	$18M	$2M	$67M	$2M	$17M	$0M	$0M
Gross Profit	$23M	$17M	$15M	($1M)	$64M	($98M)	($77M)	($84M)	($79M)
Gross Margin %	79.3%	87.6%	83.9%	-38.4%	96.6%	-6223.1%	-453.1%	-18174.7%	-31866.7%
Operating Income (EBIT)	($179M)	($184M)	($178M)	($167M)	($112M)	($156M)	($139M)	($141M)	($130M)
Operating Margin %	-617.2%	-948.7%	-1004.6%	-8613.4%	-167.0%	-9856.3%	-821.4%	-30410.6%	-52277.9%
Net Income	($199M)	($206M)	($183M)	($306M)	($134M)	($161M)	($150M)	($161M)	($143M)
Net Margin %	-686.2%	-1064.5%	-1030.9%	-15815.0%	-201.3%	-10220.1%	-886.3%	-34675.0%	-57557.4%
EBITDA	—	($169M)	($180M)	($277M)	($108M)	($136M)	($125M)	($136M)	($117M)
Earnings Per Share (EPS)	$-1.50	$-1.67	$-1.49	$-2.55	$-1.12	$-1.36	$-1.27	$-1.36	$-1.31
Shares Outstanding (M)	—	123M	122M	120M	119M	118M	118M	118M	109M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($556M)	($510M)	($396M)	($414M)	($300M)	($143M)	$9M	($91M)	($101M)	($102M)	$37M	$5M	($45M)	($8M)	($33M)	($46M)	($45M)	$8M	($61M)	($3M)	($47M)
Capital Expenditures (CapEx)	$25M	$25M	$4M	$1M	$11M	$49M	$11M	$3M	$1M	$3M	$2M	$1M	$1M	$1M	$0M	$0M	$0M	$1M	$1M	$3M	$5M
Free Cash Flow (FCF)	($580M)	($535M)	($400M)	($416M)	($311M)	($191M)	($2M)	($94M)	($102M)	($105M)	$35M	$4M	($46M)	($8M)	($34M)	($46M)	($45M)	$8M	($62M)	($6M)	($53M)
FCF Margin %	-852.9%	-607.5%	-2164.1%	-5521.2%	-328.6%	-271.8%	-3.8%	-348.1%	-324.1%	-782.7%	33.3%	15.1%	-97.9%	-27.0%	-444.0%	-1150.9%	-1758.7%	9.7%	-499.1%	-40.9%	-1680.2%
Dividends Paid	—	—	—	$18M	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($160M)	($145M)	($143M)	($108M)	($128M)	($132M)	($66M)	($102M)	($99M)
Capital Expenditures (CapEx)	$4M	$6M	$6M	$9M	$4M	$6M	$1M	$2M	$2M
Free Cash Flow (FCF)	($164M)	($151M)	($148M)	($117M)	($132M)	($137M)	($67M)	($104M)	($101M)
FCF Margin %	-565.5%	-782.2%	-835.2%	-6036.1%	-198.3%	-8694.2%	-395.0%	-22452.5%	-40653.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CYTK Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.9B	$1.4B	$1.4B	$824M	$1.0B	$841M	$534M	$290M	$211M	$295M	$170M	$115M	$133M	$83M	$78M	$53M	$78M	$123M	$87M	$155M	$170M
Cash & Cash Equivalents	$255M	$123M	$95M	$113M	$66M	$113M	$83M	$36M	$42M	$125M	$67M	$65M	$20M	$20M	$15M	$19M	$18M	$26M	$42M	$117M	$39M
Total Liabilities	$2.1B	$2.1B	$1.5B	$1.2B	$1.1B	$597M	$420M	$301M	$185M	$185M	$76M	$47M	$41M	$29M	$6M	$5M	$7M	$21M	$38M	$55M	$63M
Total Debt (Short + Long-Term)	$1.3B	$1.2B	$676M	$635M	$78M	$62M	$49M	$50M	$42M	$37M	$30M	$17M	$1M	$4M	$1M	$0M	$1M	$3M	$5M	$9M	$11M
Total Shareholders' Equity	($174M)	($660M)	($135M)	($386M)	($108M)	$244M	$113M	($11M)	$26M	$110M	$94M	$69M	$92M	$54M	$71M	$48M	$71M	$101M	$50M	$100M	$106M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CYTK viewer.

CYTK Metric Deep Dives

Other Companies in BIOTECHNOLOGY

AXSM · Axsome Therapeutics Inc — $11 billion
APGE · Apogee Therapeutics, Inc. Common Stock — $10 billion
KRYS · Krystal Biotech Inc — $10 billion
KYMR · Kymera Therapeutics Inc — $10 billion
ARWR · Arrowhead Pharmaceuticals Inc — $9 billion
PTGX · Protagonist Therapeutics Inc — $9 billion
ABVX · Abivax SA American Depositary Shares — $9 billion
CRNX · Crinetics Pharmaceuticals Inc — $9 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← CYSE All “C” companies CZA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.